慢性阻塞性肺病 COPD
Long-term maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema

Long-Acting beta2-Adrenergic Agonist
Activates beta2 airway receptors, resulting in the stimulation of intracellular adenyl cyclase and a subsequent increase in the synthesis of cyclic-3',5' adenosine monophosphate (cAMP). Elevated cAMP levels induce bronchodilation by relaxation of airway smooth muscle cells. Has much greater affinity for beta2-receptors than for beta1- (241 times) or beta3- receptors (2299 times) <20210907>

Absorption
1. Bioavailability: 30% (inhalation)
2. Onset of action: 5 minutes; Time to peak: 10 to 20 minutes
Distribution
1. Vd: 1110 L
2. Protein binding: ~60%
Metabolism
Direct glucuronidation (UGT2B7, UGT1A1, 1A7, and 1A9) and O-demethylation (primarily CYP2C9 and 2C8)
Excretion
Urine (5% to 7% unchanged); feces
Pharmacodynamics
1. Half-life elimination: 7.5 hours
2. Duration: 24 hours

Monotherapy (without use of a concomitant inhaled corticosteroid) in the treatment of asthma

Adverse events were observed in some animal reproduction studies. Beta-agonists have the potential to affect uterine contractility if administered during labor.

It is not known if olodaterol is present in breast milk

Nasopharyngitis, Skin rash, Urinary tract infection, Back pain, arthralgia, Bronchitis
Warnings: Striverdi contains benzalkonium chloride which may cause wheezing and dyspnea, espicially in asthma patients <20210907>

Two inhalations once daily (maximum: 2 inhalations per day)

No dosage adjustment necessary.

1. Mild to moderate impairment: No dosage adjustment necessary
2. Severe impairment: Has not been studied